Patent Term Extension Application for CARDAMYST™ (etripamil), Patent No. 9,227,918 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

FDA-2026-E-3811

Patent Term Extension Application for CARDAMYST™ (etripamil), Patent No. 9,227,918

Documents

Comments

Description

OPEN

Comment Period OpensApr 9, 2026

Type	Title	Posted	Comments	Status
Other	Letter from U. S. Patent and Trademark Office to FDA CDER	Apr 9, 2026	--

CDER

Patent Term Extension Application

Clark & Elbing LLP

Milestone Pharmaceuticals, Inc

CARDAMYST™ (etripamil)

Patent No. 9,227,918

OPEN